PROSTATE CANCER

A Personalized, Non-Surgical Treatment For Prostate Cancer

Cancer treatment that revolves around you.

You have more options than ever for successfully treating prostate cancer. The “best” option for you is the one that fits your life — from the specifics of your cancer and your overall health, to your age and lifestyle. The Radixact® System — the world’s only helical radiotherapy platform with 360-degree precision — gives you a highly precise and personalized treatment option that literally revolves around you. The Radixact System, the next-generation TomoTherapy platform, was designed to help you gain control over your cancer with as little impact on your romantic life and urinary and bowel function as possible.

Key treatment benefits of the Radixact System using TomoTherapy® technology for prostate cancer treatment

Ask a physician if Radixact treatment is right for you

You deserve the best possible treatment for your prostate cancer. Find a physician in your area offering the Radixact System — and find out if Radixact treatment is right for you.

  • Clinically Proven Outcomes
  • Synchronized with Target Motion
  • A Non-Surgical Option
  • Enabling Re-Treatment
  • Radixact vs Traditional Treatments

A clinically proven treatment for a wide range of prostate cancers

The Radixact System, the next-generation TomoTherapy platform, has been designed to enable doctors to more effectively and efficiently deliver precise radiation treatments to more patients. The TomoTherapy platform represented a dramatic advance in the radiation oncology field, as the only system specifically designed for integrated 3D daily image-guidance with intensity modulated radiation therapy (IG-IMRT) that will help you fight your cancer. The Radixact System is one of the most integrated, advanced systems for comprehensive cancer treatment available today and can be used to treat all prostate cancer patients, including those with organ-confined cancer or with advanced disease.

Prostate Cancer

Clinical evidence supports the use of the TomoTherapy System for the treatment of prostate cancer patients of all risk groups, with early evidence suggesting excellent clinical outcomes. The treatment regimens described in the studies reinforce the benefits of the unique capabilities of the TomoTherapy platform and what clinicians and their patients could expect to see with the Radixact System.

Radixact with Synchrony® tracks and targets your tumor in real-time*

The prostate gland can move substantially and unpredictably throughout the course of treatment — as much as half an inch in as little as 30 seconds because of normal patient bodily functions (filling of the bladder, gas in the bowel, or even slight patient movement) . Unlike any other radiation treatment, the Radixact System with Synchrony can continually track the target, and can automatically adapt and synchronize the radiation beam with movement of the prostate throughout the entire treatment session. This helps to ensure the radiation dose is delivered to the target — maximizing treatment effectiveness while minimizing dose to surrounding tissues to reduce the incidence of side effects.

*The Synchrony technology is an optional upgrade available for purchase by hospitals.

A non-invasive, non-surgical option

While surgery remains a common treatment for prostate cancers, its application may be limited by the patient’s health and the stage and location of the tumor, or the patient’s desire to avoid a surgical procedure.

Treatment with the Radixact System is an outpatient procedure that does not require incisions or general anesthesia. Most patients will not require hospitalization or a long recovery time.

Enabling re-treatment

Because the precise targeting of the Radixact System significantly reduces irradiation of surrounding healthy tissues, Radixact can be a powerful treatment option for a wider range of prostate cancer patients, including patients who have previously undergone radiation or surgical procedures, and experience a recurrence.

An effective, less disruptive treatment option

The Radixact System, the next-generation TomoTherapy platform, maximizes radiation delivered to the target — while helping minimize radiation dose to surrounding healthy tissues. The result is highly personalized treatment designed to significantly reduce the risk of the side effects that too often disrupt the lives of patients during and after treatment.

RADIXACT VS. SURGERY

Radixact treatment is an outpatient procedure that requires no incisions or general anesthesia. Most patients will not require hospitalization or a long recovery period.

RADIXACT VS. BRACHYTHERAPY

Radixact treatment eliminates the inconvenience and risk associated with radioactive seeds.

RADIXACT VS. CONVENTIONAL RADIATION THERAPY

Conventional radiation therapy typically requires patients to have treatment 5 days a week for 8 weeks. Clinicians using the Radixact System may choose to reduce this course of treatment due to the precise nature of delivery, significantly reducing the time you spend undergoing radiation treatments.

Find a Radixact Treatment Center

Learn More About Radixact Treatment

References:

1 Di Muzio NG, Fodor A, Noris Chiorda B, et al. “Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.” Clin Oncol (R Coll Radiol). 2016 Aug;28(8):490-500. doi: 10.1016/j.clon.2016.02.005.

2 Tomita N, Soga N, Ogura Y, et al. “High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes.” J Cancer Res Clin Oncol. 2016 Jul;142(7):1609-19. doi: 10.1007/s00432-016-2173-9.

3 Yamazaki H, Masui K, Suzuki G, et al. “High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer.” Cancers (Basel). 2018 Sep 10;10(9). pii: E322. doi: 1.

4 Macias VA, Barrera-Mellado I. “Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial.” BJU Int. 2019 Oct 15. doi: 10.1111/bju.14925.

5 Saldi S, Bellavita R, Lancellotta V, et al. “Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study.” Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):105-111. doi: 10.10.

6 Fodor A, Berardi G, Fiorino C, et al. “Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.” BJU Int. 2017 Mar;119(3):406-413.

Share Your Story

Educating others about your experience with the Radixact® or TomoTherapy® System can help others who face similar decisions about their own cancer treatment choices.

If you are interested in sharing your story, please fill out the form below and an Accuray representative will contact you.

Privacy Disclaimer: To protect your safety, please do not provide your personal or sensitive information, such as your medical history, on our websites. By entering any information on our websites, you understand and agree that such information will be transferred to Accuray Incorporated in the United States. Please read our Privacy Policy.